Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma

Abstract Therapeutic strategies for advanced renal cell carcinoma have advanced dramatically since the approval of immune checkpoint inhibitors. To date, four PD-L1 assays have been established as companion diagnostic tools for checkpoint inhibitors. However, all PD-L1 assays present several limitat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yoko Koh, Taigo Kato, Gaku Yamamichi, Eisuke Tomiyama, Makoto Matsushita, Koji Hatano, Atsunari Kawashima, Norio Nonomura, Motohide Uemura
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Portfolio 2025-07-01
Colección:Scientific Reports
Materias:
Clear cell renal cell carcinoma
Programed death-ligand 1 (PD-L1)
Immunohistochemistry
Next-generation sequencing
Companion diagnostics
Acceso en línea:https://doi.org/10.1038/s41598-025-05697-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares